Matthew Illian, Director of Responsible Investing, discusses the pressure being applied to corporations to protect our planet and the strategic partnership to address climate issues.
As a responsible investor, UCF is committed to strengthening our efforts and taking concrete steps toward racial justice and equality. UCF will continue to work with our partners and on behalf of our clients to ensure that their investments make a positive impact on people’s lives, communities and the world. Read more on concrete steps UCF has taken toward racial justice and equality.
US SIF’s 13th edition of Report of US Sustainable and Impact Investing Trends confirms the continued increase in responsible investing. Matthew Illian, Director of Responsible Investing shared his insight on what does this mean and why responsible investing is more important than ever?
Learn what responsible investors are talking about from Matthew Illian’s highlights of the recent fall conference of the Interfaith Center on Corporate Responsibility.
The United Church of Christ has a long and commendable legacy of turning to faith values to guide its economic practices. This legacy also guides UCF’s work in managing the assets of churches and faith-based institutions. View and download an infographic that shows the evolution of responsible investing in the UCC.
Matthew Illian, Director of Responsible Investing provides a summary and analysis of recently issued policy recommendations and legislation that affect shareholder resolutions and ESG investing.
World Environment Day falls on June 5. In commemoration, UCF is proud to share the partnerships we have forged, the work that we have accomplished and the progress of our initiatives to help address environmental issues. Read our initiatives, from our launch of the Beyond Fossil Fuels Fund to our response in addressing the climate crisis.
Today, 23.9% of voting shareholders of AbbVie, a U.S. pharmaceutical company, supported a United Church Funds-led shareholder resolution to report on the “feasibility of incorporating public concern over high drug price into the senior executive compensation arrangement.”